Sean Gilbey, MD
Critical Care Medicine · Austin, TXNPI 1184628828
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $603 and has fallen 82.7% since, to $104 in 2024.
Across 48 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$215
- GSK$132
- Regeneron Healthcare Solutions, Inc.$114
- United Therapeutics Corporation$105
- Gilead$80
- Sanofi$75
- plus $367 from 10 others
Across 23 payments — averaging $31,471 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$636K
- GSK$87K
- Teva Pharmaceuticals USA, Inc.$480
What the payments were for
- Consulting fees$262%
- Food & beverage$1,04496%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $215 |
| GSK | 7 | $132 |
| Regeneron Healthcare Solutions, Inc. | 3 | $114 |
| United Therapeutics Corporation | 5 | $105 |
| Gilead | 4 | $80 |
| Sanofi | 3 | $75 |
| Insmed, Inc. | 4 | $68 |
| Mylan Specialty L.p. | 3 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Electromed, Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $31 |
| Itamar Medical Inc | 1 | $26 |
| Philips North America LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Apria Healthcare LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$104
How this compares
$1,089 in reported general payments places this provider in the 60th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 217 | $248,094 |
| Dupixent PenDupilumab | 17 | $70,055 |
| Spiriva RespimatTiotropium Bromide | 45 | $39,214 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $22,107 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,036 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $11,761 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 171 | $7,314 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,733 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,636 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,586 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,562 |
| Roflumilast | 29 | $3,266 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,217 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,574 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 12 | $1,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $132 | $286,549275 claims |
| Boehringer IngelheimSpiriva Respimat | $215 | $39,21445 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $19 | $29,40550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Austin
- William BartekAustin$284K
- Subramaniyam RajanAustin$98K
- Matthew AndersonAustin$79K
- John HinzeAustin$28K
- Steven DavidoffPlano$364K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.